News 17.04.2024 Schlieren (Zurich), Switzerland, April 17, 2024 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2023 and took note of the Reports...
News 05.04.2024 Zurich, Switzerland - 04.04.2024 Neurimmune today announced that its collaboration partner Alexion, AstraZeneca’s Rare Disease group, initiated the Phase 3 DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 (formerly NI006) for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) (NCT06183931). ALXN2220 is an investigational human monoclonal antibody designed to deplete...
News 05.04.2024 ZURICH, Switzerland and FREMONT, California, US April 4, 2024 (GlobeNewswire). Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid...
News 26.03.2024 Schlieren, Switzerland, March 25th, 2024 – hemotune AG, a pioneering Swiss biotech company, today announced the successful closing of a CHF 14 million Series B2 round dedicated to advancing its HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads. The investment was led by Belmondo with continued support of...
News 21.03.2024 ZURICH, Switzerland and NEWTON, Massachusetts, March 20, 2024. Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the release of enhanced plasma proteomics workflows for its TrueDiscovery® unbiased discovery proteomics research services platform. The new workflows leverage an innovative plasma enrichment method, delivering deep proteome coverage with...